OP-1250 Clinical Trial for ER-Positive, HER2-Negative Breast Cancer

ClinicalTrials.gov identifier: NCT06016738

This Phase 3 randomized clinical study compares OP-1250 monotherapy with standard-of-care treatment for ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy and a CDK4/6 inhibitor.

Study availability and enrollment status may change. A California Research Institute coordinator can confirm current local availability and explain the screening process.

Request study information